Gulati S, Shank B, Straus D, Koziner B, Lee B, Mertelsmann R, Kempin S, Andreeff M , Dinsmore R, Gee T, Yopp J, Vega R, Gandola L, O'Reilly R, Clarkson B
Beyond appetite control, GLP-1 activation improves insulin sensitivity and helps regulate blood glucose levels
It is a fundamental challenge to the framing of GLP-1 medications as weight loss drugs whose cardiovascular benefits are a downstream consequence of a lighter body
have proved to be promising choices either as monotherapy or as combination therapy for patients with DKD
The approval is based on a study showing that 2.4 mg of semaglutide the generic name for Wegovy reduced the incidence of non-fatal heart attacks, non-fatal strokes, and mortality from heart disease
GLP-1 drugs like Ozempic mimic a hormone the body produces after eating, which can decrease appetite and help the body manage insulin production